Registry of 919 patients with thrombotic microangiopathies across Japan: Database of Nara Medical University during 1998-2008

Internal Medicine

Volumn 49, Issue 1, 2010, Pages 7-15

  Fujimura, Yoshihiro ^a   Matsumoto, Masanori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

ADAMTS13; HUS; TMA; TTP; USS; VWF

Indexed keywords

NEUTRALIZING ANTIBODY; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CONTROL GROUP; CONTROLLED STUDY; DATA BASE; DISEASE REGISTRY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PREGNANCY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSPLANTATION;

ADAM PROTEINS; ALGORITHMS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; JAPAN; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES;

EID: 74549138555     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2706     Document Type: Article

References (48)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 347: 589-600, 2002.
2. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 354: 1927-1935, 2006.
3. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87: 4223-4234, 1996.
4. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87: 4235-4244, 1996.
5. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98: 1654-1661, 2001.
6. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98: 1662-1666, 2001.
7. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo) 130: 475-480, 2001.
8. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276: 41059-41063, 2001.
9. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 106: 922-924, 2005.
10. Suzuki M, Murata M, Matsubara Y, et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 313: 212-216, 2004.
11. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 4: 1396-1404, 2006.
12. Manea M, Kristoffersson A, Schneppenheim R, et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 138: 651-662, 2007.
13. Furlan M, Robles R, Galbusera M, et al. von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339: 1578-1584, 1998.
14. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585-1594, 1998.
15. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112: 11-18, 2008.
16. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 88: 816-825, 1994.
17. Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH. ADAMTS 13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 49: 206-213, 2009.
18. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108: 785-791, 2001.
19. Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 9: 36-50, 2009.
20. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 74: 101-108, 2001.
21. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46: 1444-1452, 2006.
22. Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 42: 572-580, 2002.
23. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612, 1975.
24. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11: 571-575, 2005.
25. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 92: 95-100, 2007.
26. Wada H, Wakita Y, Nakase T, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 51: 255-260, 1996.
27. Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 75: 25-34, 2002.
28. Kokame K, Aoyama Y, Matsumoto M, Fujimura Y, Miyata T. Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome. J Thromb Haemost 6: 213-215, 2008.
29. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8: 286-293, 2001.
30. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 50: 1138-1143, 2007.
31. Fukusako T, Yamashita H, Omoto M, Matsuda K, Shinohara K, Fujimura Y. A case of thrombotic thrombocytopenic purpura associated with clopidogrel. Clin Neurol 47: 635-638, 2007.
32. Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int 75 (Suppl 112): S20-S24, 2009.
33. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31: 681-690, 2005.
34. Kitano K, Gibo Y, Kamijo A, et al. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica 91: ECR34, 2006.
35. Gitlow S, Goldmark C. Generalized capillary and arteriolar thrombosis. Report of two cases with a discussion of the literature. Ann Intern Med 13: 1046-1067, 1939.
36. Sato T, Hanaoka R, Ohshima M, et al. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital. Clin Exp Rheumatol 24: 454-455, 2006.
37. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thrombosis and Haemostasis 102: 371-378, 2009.
38. Kawahara M, Kanno M, Matsumoto M, Nakamura S, Fujimura Y, Ueno S. Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor. Neurology 63: 1731-1733, 2004.
39. Kanno M, Nakamura S, Kawahara M, et al. Chemotherapyresistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab. Int J Hematol 88: 345-347, 2008.
40. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 93: 3798-3802, 1999.
41. Fujimura Y, Matsumoto M, Kokame K, et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 144: 742-754, 2009.
42. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 99: 1019-1029, 2008.
43. Ko S, Okano E, Kanehiro H, et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 12: 859-869, 2006.
44. Kobayashi T, Wada H, Usui M, et al. Decreased ADAMTS13 levels in patients after living donor liver transplantation. Thromb Res 124: 541-545, 2009.
45. Pereboom IT, Adelmeijer J, van Leeuwen Y, Hendriks HG, Porte RJ, Lisman T. Development of a severe von Willebrand factor/ ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant 9: 1189-1196, 2009.
46. Wasserstein A, Hill G, Goldfarb S, Goldberg M. Recurrent thrombotic thrombocytopenic purpura after viral infection. Clinical and histologic simulation of chronic glomerulonephritis. Arch Intern Med 141: 685-687, 1981.
47. Dias PJ, Gopal S. Refractory thrombotic thrombocytopenic purpura following influenza vaccination. Anaesthesia 64: 444-446, 2009.
48. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 76: 369-380, 1997.